Appendix S1

ACKNOWLEDGEMENTS AND CONFLICT OF INTEREST

PSONET (www.psonet.eu) represents an international collaboration and is dependent on contributions from many members and advisors within the collaboration, who are gratefully acknowledged for their contribution. In particular, the authors would like to thank the collaboration of the following PSONET members: Francesco Cusano (Italy), Olivier Chosidow (France), Tony Ormerod (UK), Marcus Schmidt Egenolf (Sweden), Lidian Lecluse and Celine Busard (The Netherlands). All of the participating registries rely on contributions from many individuals who contribute to the AMC psoriasis registry, Australasian Psoriasis Registry, BADBIR, Biobadaderm, Clalit Health Services, DERMBIO, PSOBEST, PSOCARE, PsoReg and PsoBioTeq. The authors would like to acknowledge their vital ongoing support.

Funding sources: PSONET was supported by funding from the European Academy of Dermatology and Venereology (EADV) and the Italian Drug Agency (AIFA). The AMC psoriasis registry is funded by the Department of Dermatology of the Academic Medical Centre. The Australasian Psoriasis Registry was supported by unconditional funding from Epiderm, Abbott, Pfizer, Janssen-Cilag, Merck-Serono and MSD. Biobadaderm was supported by unconditional funding from the Academia Española de Dermatología y Venereología, Agencia Española de Medicamentos y Productos Sanitarios, Abbott, Schering, MSD, Wyeth, Pfizer and Janssen-Cilag. DERMBIO has received sponsoring from Abbott, Janssen-Cilag, MSD and Pfizer. PSOBEST was supported by Abbott, MSD, Pfizer, Janssen-Cilag, Biogen Idec and Medac. None of the funders participated in the analysis or preparation or reviewed the manuscript.

Conflict of interest: PD-S received travel grants for congresses from Pfizer and Janssen. IG-D received congress grants from Pfizer, Janssen, and MSD. TND is a consultant and/or speaker for Abbott, Janssen-Cilag, LEO Pharma, MSD, Novo Nordisk and Pfizer. LN is a member of the scientific board of the PSOLAR registry, which is supported by Centocor. MA has received grants and/or honoraria as a consultant, speaker, and/or advisory board member from Abbvie, Almirall, Amgen, Astellas, Biogen, Celgene, Eli Lilly, Janssen, Leo, MSD, Merck-Serono, Mundipharma, Novartis, Pfizer, Pohl-Boskamp, UCB, and Xenoprot. CB has received research support from Epiderm, Abbott, Pfizer, Janssen-Cilag, Merck-Serono and MSD. ED served as a consultant for AbbVie Laboratories, Amgen, Astellas, Celgene, Centocor Ortho Biotech Inc, Galderma, Glaxo, Janssen-Cilag, Leo Pharma, MSD, Novartis, and Pfizer Inc.; received honoraria from AbbVie Laboratories, Amgen, Celgene, Janssen-Cilag Pty Ltd, Leo Pharma, MSD, Novartis, and Pfizer Inc.; participated in speakers’ bureaus for AbbVie Laboratories, Janssen Pharmaceuticals Inc, MSD, and Pfizer Inc.; and received grants from AbbVie Laboratories, Janssen Pharmaceuticals Inc., and Pfizer Inc. PIS is principal investigator in many pharmaceutical initiated trials in her department, has received departmental research support from MSD and attended advisory board meetings for Leo Pharma and Janssen. ADC has received consultation fees from MSD and Abbott. The other authors declare no conflicts of interest.